Back
JD Health H2 Revenue to Grow 25% on Strong Pharma Sales, Nomura Says
Back
Stock News
Themes
JD Health H2 Revenue to Grow 25% on Strong Pharma Sales, Nomura Says
JD Health H2 Revenue to Grow 25% on Strong Pharma Sales, Nomura Says
Edgen Stock
·
Jan 06 2026, 02:41
Share to
Share to
Copy link
JD HEALTH
+3.49%
NMR
+0.82%
source:
[1] [Big Bank] Nomura Expects JD Health's (06618.HK) H2 Revenue Last Year to Grow 25%, Beating Expectations
Recommend
ON Semiconductor Analysis Fails to Load, Leaving Investors in the Dark
Jan 13 2026, 23:40
Analysts Project 25% Earnings Plunge for D.R. Horton
Jan 13 2026, 23:35
Cramer Blames High Interest Rates for D.R. Horton's Stock Downgrade
Jan 13 2026, 23:34
Edgen Stock·Jan 06 2026, 02:41Edgen Stock·Jan 06 2026, 02:41
Edgen Stock·Jan 06 2026, 02:41